文献速递贫血与红细胞疾病

口服铁转运蛋白抑制剂VIT-2763在健康志愿者中的首次人体I期研究

Oral ferroportin inhibitor VIT-2763: First-in-human, phase 1 study in healthy volunteers.
PubMed 文献 · Am J Hematol · 2019-11-19

这项首次人体I期研究评估了口服铁转运蛋白抑制剂VIT-2763在健康志愿者中的安全性、耐受性、药代动力学和药效学。单次剂量≥60 mg及所有多次给药后血清铁暂时下降,转铁蛋白饱和度也暂时降低,支持在非输血依赖型地中海贫血患者中开展临床研究。

要点

  • VIT-2763在健康志愿者中耐受性良好,安全性特征与安慰剂相似。
  • 单次剂量≥60 mg及所有多次给药后血清铁和转铁蛋白饱和度暂时下降。
  • 结果支持在非输血依赖型地中海贫血伴铁过载患者中启动临床研究。

核心结论

  • VIT-2763在健康志愿者中耐受性良好,安全性特征与安慰剂相似。
  • VIT-2763可暂时降低血清铁和转铁蛋白饱和度,并移动血清铁调素峰值。
  • 结果支持在非输血依赖型地中海贫血伴铁过载患者中启动临床研究。

研究设计与样本

  • 首次人体I期研究,评估口服铁转运蛋白抑制剂VIT-2763在健康志愿者中的安全性、耐受性、药代动力学和药效学。
  • 单次递增剂量阶段给予VIT-2763 5/15/60/120/240 mg或安慰剂。
  • 多次递增剂量阶段给予VIT-2763 60/120 mg每日一次、60/120 mg每日两次或安慰剂,持续7天。

主要发现

  • VIT-2763耐受性良好,无严重或重度不良事件,无因不良事件停药。
  • VIT-2763吸收相对较快,给药后15至30分钟可检测到药物水平。
  • 多次给药后吸收无明显变化,蓄积极少。
  • 单次给药后平均消除半衰期为1.9至5.3小时;多次给药后第1天为2.1至3.8小时,第7天为2.6至5.3小时。
  • 单次剂量≥60 mg及所有多次给药后血清铁平均水平暂时下降;多次给药后计算的转铁蛋白饱和度也暂时下降。

关键数值与推荐

  • 单次递增剂量阶段VIT-2763剂量为5/15/60/120/240 mg或安慰剂。
  • 多次递增剂量阶段VIT-2763剂量为60/120 mg每日一次、60/120 mg每日两次或安慰剂,持续7天。
  • 单次给药后平均消除半衰期为1.9至5.3小时;多次给药第1天为2.1至3.8小时,第7天为2.6至5.3小时。
  • 给药后15至30分钟可检测到VIT-2763水平。

临床怎么用

  • VIT-2763在健康志愿者中安全性良好,支持进一步在非输血依赖型地中海贫血伴铁过载患者中研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Restriction of iron availability by ferroportin inhibition is a novel approach to treating non-transfusion-dependent thalassemia (β-thalassemia intermedia). This first-in-human, Phase I study (https://www.clinicaltrialsregister.eu; EudraCT no. 2017-003395-31) assessed the safety, tolerability, pharmacokinetics and pharmacodynamics of single- and multiple-ascending doses (SAD and MAD) of the oral ferroportin inhibitor, VIT-2763, in healthy volunteers. Participants received VIT-2763 5/15/60/120/240 mg or placebo in the SAD phase and VIT-2763 60/120 mg once daily, VIT-2763 60/120 mg twice daily, or placebo for 7 days in the MAD phase. Seventy-two participants completed treatment. VIT-2763 was well tolerated and demonstrated a similar safety profile to the placebo. There were no serious or severe adverse events, or discontinuations due to adverse events. VIT-2763 absorption was relatively fast, with detectable levels 15 to 30 minutes post-dose. Following multiple dosing there was no apparent change in absorption and accumulation was minimal. Mean elimination half-life was 1.9 to 5.3 hours following single dosing, and 2.1 to 3.8 hours on Day 1 and 2.6 to 5.3 hours on Day 7, following repeated dosing. There was a temporary decrease in mean serum iron levels with VIT-2763 single doses ≥60 mg and all multiple doses; mean calculated transferrin saturation (only assessed following multiple dosing) also temporarily decreased. A shift in mean serum hepcidin peaks followed administration of all iron-lowering doses of VIT-2763. This effect was less pronounced after 7 days of multiple dosing (aside from with 120 mg once daily). These results support the initiation of clinical studies in patients with non-transfusion-dependent thalassemia and documented iron overload due to ineffective erythropoiesis.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Richard F, van Lier JJ, Roubert B, et al. Oral ferroportin inhibitor VIT-2763: First-in-human, phase 1 study in healthy volunteers. Am J Hematol. 2019. PMID: 31674058. doi:10.1002/ajh.25670

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。